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the synaptic cleft. However, the biological effects of these drugs seem to be more complex than their
traditionally described mechanism of action. Among their actions is the inhibition of different types of
Naþ and Kþ channels, as well as of glutamate uptake activity. The clearance of extracellular glutamate is
essential to maintain the central nervous system within physiological conditions, and this excitatory
neurotransmitter is removed from the synaptic cleft by astrocyte transporters. This transport depends
upon a hyperpolarized membrane potential in astrocytes that is mainly maintained by Kir4.1 Kþ
channels. The impairment of the Kir4.1 channel activity reduces driving force for the glutamate
transporter, resulting in an accumulation of extracellular glutamate. It has been shown that sertraline
and fluoxetine inhibit Kir4.1 Kþ channels. Recently, we demonstrated that sertraline reduces glutamate
uptake in human platelets, which contain a high-affinity Naþ-dependent glutamate uptake system, with
kinetic and pharmacological properties similar to astrocytes in the central nervous system. Considering
these similarities between human platelets and astrocytes, one might ask if sertraline could potentially
reduce glutamate clearance in the synaptic cleft and consequently modulate glutamatergic transmission.
This possibility merits investigation, since it may provide additional information regarding the
mechanism of action and perhaps the side effects of these antidepressants.
& 2017. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Sertraline (Zoloft) is a selective serotonin reuptake inhibitor
(SSRI) that is widely prescribed as an antidepressant1 and pro-
posed as a potential first-line drug to treat people with major
depression.2 In addition to its classic mechanism of action, several
lines of evidence suggest that sertraline has other biological effects
that appear to be unrelated to its inhibition of serotonin reuptake.3
Although it is widely recognized that the action of an antidepres-
sant that inhibits reuptake of serotonin (such as fluoxetine, Prozac)
can elevate the extracellular levels of this neurotransmitter in the
synaptic cleft,4,5 additional mechanisms might also be involved
with its biological and clinical effects.6–10Inc. This is an open access article u
o, PhD, Department of Mor-
rande do Sul, Rua Sarmento
zil. Tel.: þ55 51 33084536;
o).The biological activity of sertraline in fact appears to be more
complex than its traditionally described mechanism of action. For
instance, sertraline was recently reported to inhibit several types
of Naþ and Kþ channels3,7,11–15 as well as to reduce glutamate
uptake in human platelets.8 Moreover, an effect on Ca2þ channels
and on levels of cytosolic free Ca2þ in cancer cells was also
reported.16–18 Recently, several investigators have attributed a
wide range of biological effects to sertraline that are unrelated to
its action as an inhibitor of serotonin reuptake,3,7,8,12,15–17 and that
have been suggested to be implicated in the therapeutic and/or
adverse effects of this SSRI.7
Especially interesting is the inhibitory effect of sertraline (and
also fluoxetine) on Kþ channels, such as the astroglial inwardly
rectifying channel Kir4.1, which is responsible for astroglial Kþ
buffering7 and the G protein-activated inwardly rectifying Kþ
channels, Kir3.12 Particularly because the blockade of the astroglial
Kir4.1 channels was related to reduction of both Kþ buffering and
glutamate uptake, which could potentially lead to hyperexcitabil-
ity of neurons and seizure activity.7,19–21 An eventual effect of
sertraline (and fluoxetine) on glutamate neurotransmission maynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nervous system (CNS), and also potentially contribute to its clinical
activity.Glutamate uptake
Glutamate is the major excitatory neurotransmitter in the
mammalian CNS22 and is removed from the synaptic cleft by
astrocyte uptake activity, a role that is essential for the physiolo-
gical functionality of neurons.23 The removal of extracellular
glutamate mediated by excitatory amino-acid transporters (EAATs)
limits the temporal and spatial extent of glutamatergic transmis-
sion, a rapid dynamic process that allows local modulation of
signaling in the synaptic cleft.24 Although glutamate uptake
activity is widely studied, it remains an object of great interest
since it involves different levels of complexity and is modulated at
all known levels.23–25 To date, five subtypes of EAATs (EAAT 1-5)
have been identified in mammalian tissues; EAAT1 (GLAST) and
EAAT2 (GLT1) are preferentially expressed in astrocytes, and
EAAT2 is the major isoform responsible for cerebral clearance of
glutamate.23 Uptake mediated by astrocyte transporters is a high-
affinity Naþ-dependent process that removes glutamate from the
synaptic cleft, using the electrochemical Naþ and Kþ gradients
across the plasma membranes as the driving force.23
The subtypes of glutamate transporters EAAT1-3 are expressed
not only in the CNS, but also in a variety of peripheral tissues,23
including platelets,26 where EAAT2 proved to be functional as well
as the predominant carrier.27 In addition to the presence of the
main EAATs, several other similarities are shared between platelets
and astrocytes regarding glutamate uptake. Human platelets con-
tain a high-affinity Naþ-dependent glutamate uptake system, with
similar kinetic and pharmacological properties to astrocytes.28
Additionally, as observed in the CNS, glutamate may rapidly
upregulate the activities of different EAAT subtypes of human
platelets, and in this substrate-induced modulation, EAAT2 activity
plays an important role.29 Another similarity shared between
platelets and astrocytes is related to EAAT functionality, which
uses the Naþ/Kþ-electrochemical gradient as the driving
force for glutamate uptake, and is reduced by membrane
depolarization.19,30–33Kir4.1 Kþ channels
In the nervous system, the restoration of the resting potential of
the excitable cells depends on opening the Kþ channels, which is
fundamentally mediated by outwardly rectifying Kþ channels.34
However, there is another Kþ current referred to as inwardly
rectifying Kþ currents (Kir), where the current flow is reduced in
the depolarized membrane and increased when it shows a more
negative potential. Among the several types of Kir channels, Kir4.1
is considered the principal pore-forming subunit in astrocytes, and
is responsible for the strongly negative resting potential and high
resting permeability for Kþ ions in these cells. Besides their action
in Kþ buffering, the activity of Kir4.1 channels is also related to
glutamate uptake.32
Proper functioning of glutamate transport depends on a hyper-
polarized membrane potential in astrocytes, which is maintained
mainly by Kir4.1 Kþ channels.19,31–33 The reduction of Kir4.1
channel activity evokes astrocyte membrane depolarization and
impairs the driving force for the glutamate transporter, resulting in
accumulation of extracellular glutamate.21 This impairment of
glutamate uptake resulting from the depolarization inhibits the
glutamate translocation mediated by the transporter.35,36 Animbalance in the glutamate transport efficiency related to Kir4.1
was previously shown both in vitro21 and in vivo.37
Astrocytes have been considered a potential target of antide-
pressants,6,38,39 and inhibition of Kir4.1-mediated astroglial Kþ
buffering by sertraline and fluoxetine was suggested to be involved
with their potential pharmacological action.7Discussion
Glutamatergic transmission shows wide potential for modula-
tion and a high complexity of the targets involved with its
functioning, which includes different types of receptors and
transporters. As well as the possibility of pharmacological mod-
ulation of their receptors, the performance of their transporters
can also be affected by drugs. It was previously reported that some
medications, such as riluzole,40 ceftriaxone41 and ketamine,42 may
potentially affect glutamate transporter activity. This opened new
possibilities for their therapeutic application as glutamatergic
modulators.42–45
The functioning of the glutamatergic system is highly depen-
dent on glutamate uptake, which must be closely controlled and
whose transporters may be regulated at all known levels.23,25
Glutamate transporters show an affinity similar to that of recep-
tors, and compete with these for glutamate in the synaptic cleft,
reducing their activity and consequently affecting the duration of
excitatory transmissions. Moreover, they maintain the specificity
of glutamatergic signaling by avoiding spillover of glutamate
between synapses (for review, see Murphy-Royal et al.43). Hence,
the functionality of glutamatergic transmission requires fine
adjustment to be maintained under physiological conditions.
However, this system is complex and it seems to be highly subject
to modulation. The absence of extracellular metabolism for gluta-
mate and the high dependence on transporter activity to clear this
neurotransmitter are important elements of this complexity.
The uptake activity is essential to remove glutamate released by
neurons, and is mediated by astrocytic transporters that are
electrogenic and hence are much more effective at negative resting
potentials.21,23 The maintenance of this important function
depends on the hyperpolarized membrane potential of astrocytes,
which is mediated mainly by Kir4.1 channels.19,31–33 Therefore,
inhibition of astroglial channel Kir4.1 may depolarize these cells,
disrupting the driving force necessary to maintain glutamate
clearance. As a consequence of this, both the concentration and
the permanence of glutamate in the synaptic cleft would be
increased, potentiating the action of this neurotransmitter on the
glutamatergic system (Fig. 1). It is crucial to consider the inhibitory
effect of sertraline and fluoxetine on astroglial Kir4.1 channels,
since blockade of these channels by these SSRIs reduces glutamate
uptake in astrocytes.7 Notably, a sertraline-mediated decrease in
glutamate uptake was recently described in human platelets,8 and
considering the several similarities of these cells with astrocytes,
this may suggest an analogous effect in the CNS. The comparison of
a peripheral and cerebral glutamatergic system is supported by
several resemblances between platelets and astrocytes, such as the
presence of the main glutamate transporters,27 an equivalent
functionality regarding uptake28 and the possibility that uptake
is upregulated by glutamate.29 An additional similarity is the need
for a Naþ/Kþ-electrochemical gradient as a driving force for
glutamate uptake, which is disrupted by membrane depolariza-
tion.19,30–33
The comment presented here notes that an effect of SSRIs (such
as sertraline and fluoxetine) on rectifying-Kþ channels might
affect the astrocyte resting potential, making it less negative and
consequently reducing the function of glutamate transporters.
Although an action of sertraline on the glutamatergic system
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Figure 1. Representation of the tripartite glutamatergic synapse. Astrocytes are
responsible for removing glutamate released from the presynaptic terminal, mainly
through excitatory amino-acid transporter 2 (EAAT2). This uptake depends on the
electrochemical gradient of Naþ established by Naþ/Kþ-ATPase activity, and also
on a hyperpolarized membrane potential in astrocytes that is maintained mainly by
the inwardly rectifying potassium channel 4.1 (Kir4.1). The inhibition of Kir4.1
evokes astrocyte membrane depolarization and impairs the driving force for the
glutamate transporter, resulting in accumulation of extracellular glutamate. The
schematic diagrams illustrate the relationship between astrocytes with more-
negative (A) and less-negative (B) resting potentials, and physiological and reduced
glutamate uptake, respectively. Diagram B shows an astrocyte with less-negative
resting potential due to inhibition of Kir4.1 channels and higher levels of glutamate
in the synaptic cleft as a consequence of this effect. According to this proposal, a
potential inhibition of Kir4.1 channels by a selective serotonin reuptake inhibitor
might cause astrocyte depolarization and disrupt the driving force necessary to
maintain glutamate uptake. As a consequence, the temporal and spatial extent of
glutamatergic signaling would be increased, resulting in an indirect modulation of
glutamatergic transmission. Diagram C shows the glutamate transport mechanism
with stoichiometric details of EAAT2 and Naþ/Kþ-ATPase activities.
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inhibitory action on Kþ channels, particularly Kir4.1, provide
robust evidence that this SSRI might affect glutamate uptake
activity. It is important to determine if glutamate transporters
might undergo a modulation of their functionality in response to
SSRI action, considering their physiological importance and also
because they have been considered good potential therapeutic
targets.43 The possibility that SSRIs disrupt the driving force
necessary for glutamate uptake suggests that these drugs might
extent the time that this neurotransmitter remains in the synaptic
cleft, and consequently might have an unexpected modulating
effect on the glutamatergic system.
In spite of the above evidence, an appropriate experimental
evaluation is necessary to clarify if the glutamate uptake system
may actually be modulated by SSRIs. Bearing in mind the several
similarities with astrocytes, particularly with regard to the gluta-
matergic system, the ex vivo use of human platelets seems to be a
reliable model to investigate this potential effect on glutamate
uptake. Human platelets were proposed as a model for studyingthe cerebral glutamatergic system28 and were used to investigate
the effects of different neuroactive drugs under experimental
conditions in vitro.8,46 Moreover, platelets are considered by many
researchers as peripheral markers of cerebral glutamatergic dys-
function,29,47 and the suitability of their use to evaluate glutama-
tergic alterations in the CNS is supported by the impairment of
glutamate transport in platelets in a variety of neurodegenerative
diseases.26,48–52 Taking into account that several investigations
with these cells have been carried out based on their similarities to
astrocytes,8,48–52 we consider that additional in vitro studies are
essential to test our hypothesis. One possible way to evaluate this
proposal would be to measure the glutamate uptake in human
platelets obtained from patients under SSRI treatment, comparing
the kinetic profile of glutamate uptake and the clinical information
obtained during therapeutic use of the drugs.Conclusion
An eventual confirmation that SSRIs may act as glutamatergic
modulators would have significant importance, since this neuro-
transmitter system has a pivotal role in several physiological
activities of the CNS and also in different acute or chronic
neurological disorders. The potential confirmation of this hypoth-
esis could contribute to complement the information about the
mechanism of action and safety of SSRIs, as well as suggest the
possibility of reprofiling these drugs in the future.Conflict of Interest
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